Carcinoma of the Female Urethra: Reassessment of Modes of Therapy

Hopkins, Stanley C.; Vider, Manuel; Nag, Subir; Tai, Douglas L.; Soloway, Mark S.

doi:10.1016/s0022-5347(17)52482-9

Cited by 13 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After reviewing the titles, abstracts and full texts, we selected 92 studies for qualitative synthesis (Fig. 1) [1,2,4–6,8–95].…”

Section: Resultsmentioning

confidence: 99%

Urethral cancer: a comprehensive review endorsed by the Global Society of Rare Genitourinary Tumours

García‐Perdomo,

Dávila‐Raigoza,

Summers

et al. 2024

BJU International

View full text Add to dashboard Cite

ObjectiveTo determine the effectiveness and adverse effects of urethrectomy alone or as part of multimodal therapy (MMT).MethodsA comprehensive search was conducted across MEDLINE (OVID), EMBASE, LILACS and the Cochrane Central Register of Controlled Trials (CENTRAL) databases, from their inception to the present date. The study cohort comprised individuals aged 16 years and older diagnosed with urethral tumours at any stage who underwent either isolated urethrectomy or urethrectomy as an integral component of MMT.ResultsNinety‐two studies comprising 25 480 patients met the inclusion criteria. Surgical outcomes for urethral cancer vary considerably, with 5‐year overall survival (OS) ranging from 10% to 68% based on disease extent, approach, and gender. Radiotherapy (RT) alone provides 5‐year OS of approximately 40%. Combined regimens provide better outcomes compared to single modalities, including reduced recurrence and enhanced survival. However, trimodal therapy showed survival benefits only for urothelial subtypes, indicating the need to tailor management according to cancer type. MMT with neoadjuvant chemotherapy prior to surgery demonstrated the most consistent survival gains.ConclusionsThe management of urethral cancer demands a nuanced, personalised approach, accounting for factors such as tumour location, sex, and tumour stage. MMT combining surgery, chemotherapy and RT has shown the ability to enhance outcomes in advanced disease. More extensive collaborative studies through specialised centres are imperative to advance evidence‐based protocols and refine treatment in order to improve survival.

show abstract

“…After reviewing the titles, abstracts and full texts, we selected 92 studies for qualitative synthesis (Fig. 1) [1,2,4–6,8–95].…”

Section: Resultsmentioning

confidence: 99%

Urethral cancer: a comprehensive review endorsed by the Global Society of Rare Genitourinary Tumours

García‐Perdomo,

Dávila‐Raigoza,

Summers

et al. 2024

BJU International

View full text Add to dashboard Cite

show abstract

“…Hopkins et al [14] reported on 15 patients with malignant urethral neoplasms. 13 % of the patients had low stage disease (A or B) and did well with surgical treatment alone, while 27 % of the patients had advanced disease (D 1 or greater) and died rapidly of metastases.…”

Section: Discussionmentioning

confidence: 99%

“…13 % of the patients had low stage disease (A or B) and did well with surgical treatment alone, while 27 % of the patients had advanced disease (D 1 or greater) and died rapidly of metastases. Of the 9 patients in the group with local extention of their disease (stage C), 67% died, most often from inadequate control of local disease [14]. Good results, especially with lower stage dis ease is obtained with combined therapy; usually irradia tion of the tumor site followed by radical surgery [12], Squamous cell carcinoma is the most common ure thral tumor and usually involves the distal or entire ure thra [8].…”

Section: Discussionmentioning

confidence: 99%

Primary Transitional Cell Carcinoma of the Female Urethra with Features of Clear Cell Adenocarcinoma

et al. 1985

View full text Add to dashboard Cite

Primary malignant urethral neoplasms are unusual in women. Those of mixed histologic type are so rare as to define adequate documentation. We report the case of an elderly black woman with an urethral carcinoma which had features of a transitional cell carcinoma as well as clear cell adenocarcinoma. The histologic and ultrastructural features are presented and the histogenesis is discussed. Although the patient had both high grade and high stage disease and failed initially after external beam radiation therapy, she is alive and well, without evidence of recurrent disease, 19 months after anterior exenteration.

show abstract

Localized urethral cancer in women

Mayer

Fowler

Clayton

1987

Cancer

View full text Add to dashboard Cite

The results of treatments for localized carcinoma of the urethra were assessed in 21 consecutive women treated at our institutions over a twenty year period. Only one of the tumors was confined to the distal urethra. Eighty-six percent invaded the periurethral tissues and 24% were known to be associated with regional lymph node metastases. Fifty-seven percent were adenocarcinomas. Five patients refused active therapeutic intervention and expired within one to 30 months following diagnosis. Sixteen patients were treated with extirpative surgery, radiation therapy, or combinations of the two. Four are free of disease at one, four, eleven, and 15 years after treatment. Nine developed pelvic recurrences, two developed pelvic recurrences and distant metastases and one developed distant metastases only from six to 72 months (mean, 19 months) after initial treatment. Eight of these 12 patients died at two to 13 months (mean, 8 months) after secondary treatment, two are alive with residual pelvic tumor, and two are clinically free of disease at 7 and 48 months. Only six patients were known to have distant metastases at the time of death and five of these six had adenocarcinomas. Advanced localized urethral cancer in women is difficult to eradicate and usually fatal.

show abstract

Carcinoma of the Female Urethra: Reassessment of Modes of Therapy

Cited by 13 publications

References 12 publications

Urethral cancer: a comprehensive review endorsed by the Global Society of Rare Genitourinary Tumours

Urethral cancer: a comprehensive review endorsed by the Global Society of Rare Genitourinary Tumours

Primary Transitional Cell Carcinoma of the Female Urethra with Features of Clear Cell Adenocarcinoma

Localized urethral cancer in women

Contact Info

Product

Resources

About